Disease: refractory multiple myeloma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4551538
Disease: refractory multiple myeloma
refractory multiple myeloma 		0.020 Biomarker disease BEFREE Elotuzumab, a humanized immunoglobulin G1 monoclonal antibody targeted against signaling lymphocytic activation molecule F7 (SLAMF7), has recently been used in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma. 29635485 2018
CUI: C4551538
Disease: refractory multiple myeloma
refractory multiple myeloma 		0.020 GeneticVariation disease BEFREE Elotuzumab, targeting signaling lymphocytic activation molecule family 7 (SLAMF7), has been approved in combination with lenalidomide and dexamethasone (ELd) for relapsed/refractory multiple myeloma (MM) based on the findings of the phase III randomized trial ELOQUENT-2 (NCT01239797). 29531651 2018